Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | FLT4 | P35916 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509533 | 0.82 | NOS2 (0.42) | NOS2KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL30954596 | 0.77 | NOS2 (0.41) | NOS2EPHX1KCNH2HRH2ACACB | |
| SCHEMBL6344963 | 0.74 | — | — | |
| SCHEMBL84454 | 0.72 | — | — | |
| SCHEMBL6055220 | 0.72 | MEN1 (0.43) | EPHX1HRH2ROCK2ROCK1 | |
| SCHEMBL9326757 | 0.72 | MEN1 (0.43) | EPHX1HRH2ROCK2ROCK1 | |
| SCHEMBL2170749 | 0.70 | NOS2 (0.33) | NOS2ROCK1 | |
| Hydrochloric Acid SCHEMBL20897673 | 0.70 | — | — | |
| SCHEMBL17824705 | 0.69 | KCNH2 (0.39) | NOS2KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL1484347 | 0.69 | EPHX1 (0.44) | EPHX1LRRK2FLT4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025040546-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-02-27 | — | — | WO | claimed |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2022-03-01 | — | — | US | claimed |
| EP-2560969-A1 | 4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2013-02-27 | — | — | EP | claimed |
| WO-2011133734-A1 | 4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-27 | — | — | WO | claimed |
| EP-4626865-A1 | CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025040546-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024118810-A1 | CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS | PROTEGO BIOPHARMA, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | NOS2 2731/4885EPHX1 4421/4885LRRK2 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.